[HTML][HTML] Swiss consensus recommendations on urinary tract infections in children
…, L Kottanattu, PM Meyer Sauteur, P Paioni… - European journal of …, 2021 - Springer
The kidneys and the urinary tract are a common source of infection in children of all ages,
especially infants and young children. The main risk factors for sequelae after urinary tract …
especially infants and young children. The main risk factors for sequelae after urinary tract …
Improved Diagnostics Help to Identify Clinical Features and Biomarkers That Predict Mycoplasma pneumoniae Community-acquired Pneumonia in Children
…, L Ambroggio, M Seiler, P Paioni… - Clinical Infectious …, 2020 - academic.oup.com
Background There are no reliable signs or symptoms that differentiate Mycoplasma
pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies. …
pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies. …
[HTML][HTML] Discordant impact of HLA on viral replicative capacity and disease progression in pediatric and adult HIV infection
E Adland, P Paioni, C Thobakgale, L Laker… - PLoS …, 2015 - journals.plos.org
HLA class I polymorphism has a major influence on adult HIV disease progression. An
important mechanism mediating this effect is the impact on viral replicative capacity (VRC) of the …
important mechanism mediating this effect is the impact on viral replicative capacity (VRC) of the …
Is breastfeeding an equipoise option in effectively treated HIV-infected mothers in a high-income setting?
…, B Martinez de Tejada, D Nadal, P Paioni… - Swiss medical …, 2018 - zora.uzh.ch
Combined antiretroviral treatment (cART) has reduced mother-to-child transmission (MTCT)
of the human immunodeficiency virus (HIV) to virtually zero in industrialised countries, …
of the human immunodeficiency virus (HIV) to virtually zero in industrialised countries, …
Diagnosis of Mycoplasma pneumoniae Pneumonia with Measurement of Specific Antibody-Secreting Cells
Methods Pediatric patients with CAP (n= 152) and control subjects (n= 156) were enrolled
from May 2016 to April 2017 after written informed consent. Inclusion criteria for patients with …
from May 2016 to April 2017 after written informed consent. Inclusion criteria for patients with …
[HTML][HTML] Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of …
…, R Bologna, NP Ruz, LP Tato, P Paioni… - …, 2023 - thelancet.com
Background Integrase inhibitor (INSTI) with boosted darunavir (DRV/r), a regimen with a
high-resistance barrier, avoiding NRTI toxicities, might be a switching option in children living …
high-resistance barrier, avoiding NRTI toxicities, might be a switching option in children living …
HLA-A* 7401–mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B* 5703
The potential contribution of HLA-A alleles to viremic control in chronic HIV type 1 (HIV-1)
infection has been relatively understudied compared with HLA-B. In these studies, we show …
infection has been relatively understudied compared with HLA-B. In these studies, we show …
[HTML][HTML] Nef-specific CD8+ T cell responses contribute to HIV-1 immune control
E Adland, JM Carlson, P Paioni, H Kløverpris… - PloS one, 2013 - journals.plos.org
Recent studies in the SIV-macaque model of HIV infection suggest that Nef-specific CD8+ T-cell
responses may mediate highly effective immune control of viraemia. In HIV infection Nef …
responses may mediate highly effective immune control of viraemia. In HIV infection Nef …
[HTML][HTML] Sex differences in antiretroviral therapy initiation in pediatric HIV infection
M Mori, E Adland, P Paioni, A Swordy, L Mori, L Laker… - PloS one, 2015 - journals.plos.org
The incidence and severity of infections in childhood is typically greater in males. The basis
for these observed sex differences is not well understood, and potentially may facilitate novel …
for these observed sex differences is not well understood, and potentially may facilitate novel …
[HTML][HTML] Pharmacogenetic analysis of voriconazole treatment in children
R Tilen, P Paioni, AN Goetschi, R Goers, I Seibert… - Pharmaceutics, 2022 - mdpi.com
Voriconazole is among the first-line antifungal drugs to treat invasive fungal infections in
children and known for its pronounced inter- and intraindividual pharmacokinetic variability. …
children and known for its pronounced inter- and intraindividual pharmacokinetic variability. …